Mayeux R (2004) Biomarkers: potential uses and limitations. NeuroRx 1(2):182–188. https://doi.org/10.1602/neurorx.1.2.182

Article  PubMed  PubMed Central  Google Scholar 

Mohapatra D, Jena S, Prusty SK et al (2020) Biomarkers of Alzheimer’s Disease: a review. Sys Rev Pharm. https://doi.org/10.31838/srp.2020.6.24

Article  Google Scholar 

Jeromin A, Bowser R (2017) Biomarkers in neurodegenerative diseases. Adv Neurobiol 15:491–528. https://doi.org/10.1007/978-3-319-57193-5_20

Article  PubMed  Google Scholar 

Rachakonda V, Pan TH, Le WD (2004) Biomarkers of neurodegenerative disorders: how good are they? Cell Res 14(5):347–358. https://doi.org/10.1038/sj.cr.7290235

Article  CAS  PubMed  Google Scholar 

Ravnik-Glavač M, Glavač D (2020) Circulating RNAs as potential biomarkers in amyotrophic lateral sclerosis. Int J Mol Sci 21(5):1714. https://doi.org/10.3390/ijms21051714

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang J, Kim JW, Heo H et al (2021) Identification of BAG2 and cathepsin D as plasma biomarkers for Parkinson’s Disease. Clin Transl Sci 14(2):606–616. https://doi.org/10.1111/cts.12920

Article  CAS  PubMed  Google Scholar 

García-Gutiérrez MS, Navarrete F, Sala F et al (2020) Biomarkers in psy-chiatry: concept, definition, types and relevance to the clinical reality. Front Psychiatry 11:432. https://doi.org/10.3389/fpsyt.2020.00432

Article  PubMed  PubMed Central  Google Scholar 

Dhama K, Latheef SK, Dadar M et al (2019) Biomarkers in stress related diseases/disorders: di-agnostic, prognostic, and therapeutic values. Front Mol Biosci 6:91. https://doi.org/10.3389/fmolb.2019.00091

Article  CAS  PubMed  PubMed Central  Google Scholar 

Califf RM (2018) Biomarker definitions and their applications. Exp Biol Med 243(3):213–221. https://doi.org/10.1177/1535370217750088

Article  CAS  Google Scholar 

Henry NL, Hayes DF (2012) Cancer biomarkers. Mol Oncol 6(2):140–146. https://doi.org/10.1016/j.molonc.2012.01.010

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cova I, Priori A (2018) Diagnostic biomarkers for Parkinson’s disease at a glance: where are we? J Neural Transm 125(10):1417–1432. https://doi.org/10.1007/s00702-018-1910-4

Article  CAS  PubMed  Google Scholar 

Chen JJ, Lu TP, Chen YC (2015) Predictive biomarkers for treatment selection: statistical considerations. Biomark Med 9(11):1121–1135. https://doi.org/10.2217/bmm.15.84

Article  CAS  PubMed  Google Scholar 

Hampel H, Blennow K (2004) CSF tau and β-amyloid as biomarkers for mild cognitive impairment. Dialogues Clin Neurosci 6(4):379–390. https://doi.org/10.31887/DCNS.2004.6.4/hhampel

Article  PubMed  PubMed Central  Google Scholar 

Kany S, Vollrath JT, Relja B (2019) Cytokines in inflammatory disease. Int J Mol Sci 20(23):6008. https://doi.org/10.3390/ijms20236008

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6(10):a016295. https://doi.org/10.1101/cshperspect.a016295

Article  PubMed  PubMed Central  Google Scholar 

Ntetsika T, Papathoma PE, Markaki I (2021) Novel targeted therapies for Parkinson’s disease. Mol Med 27(1):17. https://doi.org/10.1186/s10020-021-00279-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kon T, Tomiyama M, Wakabayashi K (2020) Neuropathology of Lewy body disease: Clinicopathological crosstalk be-tween typical and atypical cases. Neuropathology 40(1):30–39. https://doi.org/10.1111/neup.12597

Article  CAS  PubMed  Google Scholar 

Reeve AK, Grady JP, Cosgrave EM et al (2018) Mitochondrial dys-function within the synapses of substantia nigra neurons in Parkinson’s disease. NPJ Parkinsons Dis 4(1):1–10. https://doi.org/10.1038/s41531-018-0044-6

Article  Google Scholar 

Le W, Dong J, Li S et al (2017) Can biomarkers help the early diagnosis of parkinson’s disease? Neurosci Bull 33(5):535–542. https://doi.org/10.1007/s12264-017-0174-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fagan AM, Holtzman DM (2010) Cerebrospinal fluid biomarkers of Alzheimer’s disease. Biomark Med 4(1):51–63. https://doi.org/10.2217/BMM.09.83

Article  CAS  PubMed  Google Scholar 

Buddhala C, Campbell MC, Perlmutter JS, Kotzbauer PT (2015) Correlation between decreased CSF α-synuclein and Aβ1–42 in Parkinson disease. Neurobiol Aging 36(1):476–484. https://doi.org/10.1016/j.neurobiolaging.2014.07.043

Article  CAS  PubMed  Google Scholar 

Mita Y, Kataoka Y, Saito Y et al (2018) Distribution of oxidized DJ-1 in Parkinson’s disease-related sites in the brain and in the peripheral tissues: effects of aging and a neurotoxin. Sci Rep 8(1):12056. https://doi.org/10.1038/s41598-018-30561-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

He R, Yan X, Guo J et al (2018) Recent advances in biomarkers for parkinson’s disease. Front Aging Neurosci 10:305. https://doi.org/10.3389/fnagi.2018.00305

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sathe G, Na CH, Renuse S et al (2019) Quantitative proteomic profil-ing of cerebrospinal fluid to identify candidate biomarkers for alzheimer’s disease. Proteomics Clin Appl 13(4):e1800105. https://doi.org/10.1002/prca.201800105

Article  CAS  PubMed  Google Scholar 

Gómez-Benito M, Granado N, García-Sanz P et al (2020) Modeling Parkinson’s Disease With the Alpha-Synuclein Protein. Front Pharmacol 11:356. https://doi.org/10.3389/fphar.2020.00356

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wakabayashi K, Tanji K, Mori F et al (2007) The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27(5):494–506. https://doi.org/10.1111/j.1440-1789.2007.00803.x

Article  PubMed  Google Scholar 

Yang HJ, Vainshtein A, Maik-Rachline G et al (2016) G protein-coupled receptor 37 is a negative regulator of oli-godendrocyte differentiation and myelination. Nat Commun 7:10884. https://doi.org/10.1038/ncomms10884

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu B, Mosienko V, Vaccari Cardoso B (2018) Glio- and neuro-protection by prosaposin is mediated by orphan G-protein coupled receptors GPR37L1 and GPR37. Glia 66(11):2414–2426. https://doi.org/10.1002/glia.23480

Article  PubMed  PubMed Central  Google Scholar 

Hebron ML, Lonskaya I, Sharpe K et al (2013) Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6). J Bio Chem 288(6):4103–4115. https://doi.org/10.1074/jbc.M112.419945

Article  CAS  Google Scholar 

Marazziti D, Golini E, Mandillo S et al (2004) Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson’s disease-associated GPR37/parkin-associated endo-thelin-like receptor. Proc Nat Acad Sci USA 101(27):10189–10194. https://doi.org/10.1073/pnas.0403661101

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morató X, Garcia-Esparcia P, Argerich J et al (2021) Ecto-GPR37: a potential biomarker for Parkinson’s dis-ease. Transl Neurodegener 10(1):8. https://doi.org/10.1186/s40035-021-00232-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berti V, Pupi A, Mosconi L (2011) PET/CT in diagnosis of movement disorders. Ann NY Acad Sci 1228:93–108. https://doi.org/10.1111/j.1749-6632.2011.06025.x

Article  CAS  PubMed  Google Scholar 

Yeshokumar AK, Saylor D, Kornberg MD et al (2015) Evidence for the importance of vitamin D status in neu-rologic conditions. Curr Treat Options Neurol 17(12):51. https://doi.org/10.1007/s11940-015-0380-3

Article  PubMed  Google Scholar 

Malek N, Lawton MA, Swallow DM et al (2016) Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson’s disease. Mov Disord 31(10):1518–1526. https://doi.org/10.1002/mds.26698

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ascherio A, LeWitt PA, Xu K et al (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66(12):1460–1468. https://doi.org/10.1001/archneurol.2009.247

Article  PubMed  PubMed Central  Google Scholar 

Lawton M, Baig F, Toulson G, Morovat A, Evetts SG, Ben-Shlomo Y, Hu MT (2020) Blood biomarkers with Parkin-son’s disease clusters and prognosis: The oxford discovery cohort. Mov Disord 35(2):279–287. https://doi.org/10.1002/mds.27888

Article